Denali Therapeutics (DNLI) Return on Sales (2018 - 2023)
Historic Return on Sales for Denali Therapeutics (DNLI) over the last 7 years, with Q2 2024 value amounting to 331.22%.
- Denali Therapeutics' Return on Sales fell 3318400.0% to 331.22% in Q2 2024 from the same period last year, while for Jun 2024 it was 331.22%, marking a year-over-year decrease of 3308400.0%. This contributed to the annual value of 0.44% for FY2023, which is 25700.0% up from last year.
- Latest data reveals that Denali Therapeutics reported Return on Sales of 331.22% as of Q2 2024, which was down 3318400.0% from 0.46% recorded in Q1 2024.
- Denali Therapeutics' 5-year Return on Sales high stood at 0.77% for Q4 2020, and its period low was 331.22% during Q2 2024.
- In the last 5 years, Denali Therapeutics' Return on Sales had a median value of 6.11% in 2021 and averaged 28.92%.
- As far as peak fluctuations go, Denali Therapeutics' Return on Sales skyrocketed by 123400bps in 2020, and later crashed by -3318400bps in 2024.
- Denali Therapeutics' Return on Sales (Quarter) stood at 0.77% in 2020, then crashed by -878bps to 6.01% in 2021, then tumbled by -60bps to 9.6% in 2022, then skyrocketed by 95bps to 0.44% in 2023, then plummeted by -75286bps to 331.22% in 2024.
- Its last three reported values are 331.22% in Q2 2024, 0.46% for Q1 2024, and 0.44% during Q4 2023.